|Daily Range||$67.11 - $67.84|
|52-Week Range||$50.19 - $70.52|
|Dividend (Yield)||$0.00 (2.4%)|
|Average Daily Volume||408,738|
|Current FY EPS||$4.07|
News & Commentary
Let’s take a look back at how Halozyme, Roche, ImmunoGen, and Gilead Sciences achieved the three biggest medical advances of 2013.
As 2013 draws to a close, let’s take a look back at Halozyme’s volatile performance throughout the year and review its key collaborations with ViroPharma (Shire), Roche, Baxter, and Pfizer.
Race for new hepatitis C therapy riddled with patent complications.
Let’s take a look back at Immunomedics’ volatile performance throughout 2013 and see how it measures up to Seattle Genetics, ImmunoGen, and Roche -- companies that are also developing targeted cancer treatments.
Edivoxetine failure dampens Lilly's R&D efforts
Institutional investments in Galena Biopharma have increased significantly.
The invention of polymerase chain reaction, or PCR, in 1983 may not be directly relevant to everyday investors, but it has gone a long way in spurring innovation in biopharmaceuticals, biotech crops, and industrial biotech. If you own a company in one of those industries, then it's likely that you should pay your respects to PCR.
Gilead Sciences, Johnson & Johnson, Pharmacyclics, and AbbVie could make health care headlines today. Here’s why.
From new drugs and devices to first-time FDA actions and new health reform laws, the health-care sector was a breeding ground for innovation in 2013. Here are the five "firsts" in the sector that you need to know about.
Celldex's offering puts acquisition/partnership rumors by the likes of Roche, Amgen, or Alexion on the back burner. It also raises significant questions prior to a major data release. Does it change the outlook for the Celldex's stock?